Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

File image of medicines. PA
NI Protocol

EU adopts laws to ensure continued supply of medicines from Britain to Northern Ireland

The issue stems from the outworkings of the NI Protocol, which means NI remains covered by the EU’s pharmaceutical regulations.

THE EUROPEAN UNION Council has adopted legislation to ensure medicines can continue to flow unimpeded from Britain into Northern Ireland.

The issues surrounding medicines stem from the outworkings of the NI Protocol, a part of the Brexit deal which means Northern Ireland remains covered by the EU’s pharmaceutical regulations.

As Northern Ireland receives most of its medicines from suppliers in Britain, there had been concerns that their movement could be impeded when grace periods end.

Instead, European Commission vice president Maros Sefcovic announced proposed new legislation last year to tackle the issue.

The EU Council said today it has now adopted the directive and regulations to ensure the continued supply of medicines to Northern Ireland, as well as Cyprus, Ireland and Malta.

A statement said: “These texts will enter into force on the day of their publication in the Official Journal of the European Union, which is expected in the next few days.

“The measures will apply retroactively from January 1 2022.

The aim of the directive is to preserve the uninterrupted supply of medicinal products for human use in Northern Ireland after the withdrawal of the United Kingdom, under the protocol on Ireland/Northern Ireland.

“It will also, exceptionally and for a transitional period of three years, allow medicinal products from the United Kingdom to be placed on the market in Ireland, Malta and Cyprus under derogations from the requirement for authorisation holders to be established in the European Union.

“The regulation is closely linked to the directive and is aimed at ensuring the supply of investigational medicinal products to the same markets.”

The council said the move would “facilitate the implementation of the protocol on Ireland/Northern Ireland on the ground”.

The EU law change will allow Britain-based pharma suppliers to maintain their current regulatory arrangements.

It will mean companies in Britain can continue to act as a hub for the supply of generic medicines to Northern Ireland, without the need to establish bases in the region.

Author
Press Association
Your Voice
Readers Comments
2
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel